These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34115146)

  • 41. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.
    Zhou M; Zhou Y; Liao H; Rowland BC; Kong X; Arvold ND; Reardon DA; Wen PY; Lin AP; Huang RY
    Neuro Oncol; 2018 Aug; 20(9):1262-1271. PubMed ID: 29438510
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
    BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.
    Wu CC; Jain R; Radmanesh A; Poisson LM; Guo WY; Zagzag D; Snuderl M; Placantonakis DG; Golfinos J; Chi AS
    AJNR Am J Neuroradiol; 2018 Oct; 39(10):1814-1820. PubMed ID: 30190259
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hybrid 11C-MET PET/MRI Combined With "Machine Learning" in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016.
    Kebir S; Weber M; Lazaridis L; Deuschl C; Schmidt T; Mönninghoff C; Keyvani K; Umutlu L; Pierscianek D; Forsting M; Sure U; Stuschke M; Kleinschnitz C; Scheffler B; Colletti PM; Rubello D; Rischpler C; Glas M
    Clin Nucl Med; 2019 Mar; 44(3):214-220. PubMed ID: 30516675
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma.
    Kebir S; Lazaridis L; Weber M; Deuschl C; Stoppek AK; Schmidt T; Mönninghoff C; Blau T; Keyvani K; Umutlu L; Pierscianek D; Forsting M; Stuschke M; Antoch G; Sure U; Kleinschnitz C; Scheffler B; Colletti PM; Rubello D; Herrmann K; Glas M
    Clin Nucl Med; 2019 Jun; 44(6):e375-e381. PubMed ID: 30985412
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.
    Verburg N; Koopman T; Yaqub MM; Hoekstra OS; Lammertsma AA; Barkhof F; Pouwels PJW; Reijneveld JC; Heimans JJ; Rozemuller AJM; Bruynzeel AME; Lagerwaard F; Vandertop WP; Boellaard R; Wesseling P; de Witt Hamer PC
    Neuro Oncol; 2020 Mar; 22(3):412-422. PubMed ID: 31550353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Physiological MRI Biomarkers in the Differentiation Between Glioblastomas and Solitary Brain Metastases.
    Heynold E; Zimmermann M; Hore N; Buchfelder M; Doerfler A; Stadlbauer A; Kremenevski N
    Mol Imaging Biol; 2021 Oct; 23(5):787-795. PubMed ID: 33891264
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Accelerated progression of IDH mutant glioma after first recurrence.
    Miller JJ; Loebel F; Juratli TA; Tummala SS; Williams EA; Batchelor TT; Arrillaga-Romany I; Cahill DP
    Neuro Oncol; 2019 May; 21(5):669-677. PubMed ID: 30668823
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intratumoral heterogeneity of oxygen metabolism and neovascularization uncovers 2 survival-relevant subgroups of IDH1 wild-type glioblastoma.
    Stadlbauer A; Zimmermann M; Doerfler A; Oberndorfer S; Buchfelder M; Coras R; Kitzwögerer M; Roessler K
    Neuro Oncol; 2018 Oct; 20(11):1536-1546. PubMed ID: 29718366
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.
    Tatekawa H; Hagiwara A; Uetani H; Yao J; Oughourlian TC; Bahri S; Wang C; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Pope WB; Salamon N; Ellingson BM
    J Neurooncol; 2020 Sep; 149(2):337-346. PubMed ID: 32929644
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular Subtype Classification in Lower-Grade Glioma with Accelerated DTI.
    Aliotta E; Nourzadeh H; Batchala PP; Schiff D; Lopes MB; Druzgal JT; Mukherjee S; Patel SH
    AJNR Am J Neuroradiol; 2019 Sep; 40(9):1458-1463. PubMed ID: 31413006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
    Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
    Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is intracranial volume a risk factor for IDH-mutant low-grade glioma? A case-control study.
    Sagberg LM; Fyllingen EH; Hansen TI; Strand PS; Håvik AL; Sundstrøm T; Corell A; Jakola AS; Salvesen Ø; Solheim O
    J Neurooncol; 2022 Oct; 160(1):101-106. PubMed ID: 36029398
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic accuracy of proton magnetic resonance spectroscopy and perfusion-weighted imaging in brain gliomas follow-up: a single institutional experience.
    Anselmi M; Catalucci A; Felli V; Vellucci V; Di Sibio A; Gravina GL; Di Staso M; Di Cesare E; Masciocchi C
    Neuroradiol J; 2017 Jun; 30(3):240-252. PubMed ID: 28627984
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis.
    Thust SC; Hassanein S; Bisdas S; Rees JH; Hyare H; Maynard JA; Brandner S; Tur C; Jäger HR; Yousry TA; Mancini L
    Eur Radiol; 2018 Sep; 28(9):3779-3788. PubMed ID: 29572636
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Machine Learning-Based Prediction of Glioma
    Stadlbauer A; Nikolic K; Oberndorfer S; Marhold F; Kinfe TM; Meyer-Bäse A; Bistrian DA; Schnell O; Doerfler A
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539436
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI.
    Lin Y; Xing Z; She D; Yang X; Zheng Y; Xiao Z; Wang X; Cao D
    Neuroradiology; 2017 Jun; 59(6):555-562. PubMed ID: 28474187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma.
    Liu Z; Zhang T; Jiang H; Xu W; Zhang J
    Acad Radiol; 2019 Aug; 26(8):1062-1070. PubMed ID: 30393056
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.
    Brendle C; Hempel JM; Schittenhelm J; Skardelly M; Tabatabai G; Bender B; Ernemann U; Klose U
    Clin Neuroradiol; 2018 Sep; 28(3):421-428. PubMed ID: 28488024
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era.
    Tom MC; Varra V; Leyrer CM; Park DY; Chao ST; Yu JS; Suh JH; Reddy CA; Balagamwala EH; Broughman JR; Kotagal KA; Vogelbaum MA; Barnett GH; Ahluwalia MS; Peereboom DM; Prayson RA; Stevens GHJ; Murphy ES
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1099-1105. PubMed ID: 31022510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.